Supplemental Figure S1. CD20 immunotherapy does not significantly prolong the survival of IL-10$^{-/-}$ mice given BL3750 cells. Survival of wild type or IL-10$^{-/-}$ mice given 10^6 BL3750 cells on day 0 with CD20 (●) or control (○) mAb (250 μg) given on days 1 and 7 (arrowheads). Significant cumulative survival differences between groups treated with CD20 versus control mAb are indicated. All mice that survived >50 days (as shown) remained disease free for ≥6 months.

Supplemental Figure S2. TLR activation enhances macrophage antibody-dependent phagocytosis but not BL3750 cell proliferation, survival, or CD20 expression in vitro. (A) Phagocytosis of CD20 mAb-coated CFSE-labeled B cells by poly I:C-, LPS- or CpG- treated macrophages was assessed by flow cytometry. Values indicate mean frequencies of monocytes containing CFSE-labeled B cells. **(B)** TLR agonists or IL-10 do not affect BL3750 cell growth, survival or CD20 expression in vitro. BL3750 cells were CSFE-labeled and cultured with TLR agonists (25 μg/ml) or IL-10 (10 ng/ml). Representative histograms show cell divisions (48-72 h), viable cell frequencies (48 h), and CD20 expression (thick line) relative to background staining (thin line) with an isotype-matched control mAb (48 h, numbers indicate mean fluorescence intensities) for one of 2 experiments with similar results.



Supplemental figure 1
Horikawa, Minard-Colin et al.



Supplemental figure 2
Horikawa, Minard-Colin et al.